{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T11:21:39Z","timestamp":1778412099808,"version":"3.51.4"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.biopha.2020.110582","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T12:53:38Z","timestamp":1596113618000},"page":"110582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19"],"prefix":"10.1016","volume":"130","author":[{"given":"Ulf","family":"Norinder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrud","family":"Tuck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalle","family":"Norgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vesna","family":"Munic Kos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2020.110582_bib0005","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.biopha.2020.110582_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.293","article-title":"Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases","volume":"5","author":"Al-Bari","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.biopha.2020.110582_bib0015","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: an old drug against today\u2019s diseases?","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.biopha.2020.110582_bib0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol. J."},{"key":"10.1016\/j.biopha.2020.110582_bib0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","author":"Gordon","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2020.110582_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.biopha.2020.110582_bib0035","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.xphs.2018.11.001","article-title":"Quantification of intracellular accumulation and retention of lysosomotropic macrocyclic compounds by high-throughput imaging of lysosomal changes","volume":"108","author":"Easwaranathan","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2020.110582_bib0040","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/0006-2952(74)90174-9","article-title":"Commentary. Lysosomotropic agents","volume":"23","author":"De Duve","year":"1974","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110582_bib0045","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/dmd.118.084541","article-title":"Quantitation of lysosomal trapping of basic lipophilic compounds using in vitro assays and in silico predictions based on the determination of the full pH profile of the endo-\/lysosomal system in rat hepatocytes","volume":"47","author":"Schmitt","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2020.110582_bib0050","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1248\/bpb.b13-00423","article-title":"Subcellular distribution of azithromycin and clarithromycin in rat alveolar macrophages (NR8383) in vitro","volume":"36","author":"Togami","year":"2013","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.biopha.2020.110582_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbi.2017.12.021","article-title":"Cellular accumulation and lipid binding of perfluorinated alkylated substances (PFASs) - a comparison with lysosomotropic drugs","volume":"281","author":"Sanchez Garcia","year":"2018","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.biopha.2020.110582_bib0060","doi-asserted-by":"crossref","first-page":"5632","DOI":"10.1021\/jm300647f","article-title":"Probing the interactions of macrolide antibiotics with membrane-mimetics by NMR spectroscopy","volume":"55","author":"Kosol","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2020.110582_bib0065","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1021\/acsmedchemlett.7b00499","article-title":"Azithromycin-induced changes to bacterial membrane properties monitored","volume":"9","author":"Gh","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2020.110582_bib0070","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1021\/mp200641e","article-title":"Cationic amphiphilic drugs cause a marked expansion of apparent lysosomal volume: implications for an intracellular distribution-based drug interaction","volume":"9","author":"Funk","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2020.110582_bib0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082481","article-title":"The contribution of lysosomotropism to autophagy perturbation","volume":"8","author":"Ashoor","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2020.110582_bib0080","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/15548627.2018.1474314","article-title":"Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion","volume":"14","author":"Mauthe","year":"2018","journal-title":"Autophagy"},{"key":"10.1016\/j.biopha.2020.110582_bib0085","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cellimm.2012.09.007","article-title":"Impairment of lysosomal functions by azithromycin and chloroquine contributes to anti-inflammatory phenotype","volume":"279","author":"Nuji\u0107","year":"2012","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.biopha.2020.110582_bib0090","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1517\/17425255.2012.691165","article-title":"Drug-drug interactions involving lysosomes: mechanisms and potential clinical implications","volume":"8","author":"Logan","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.biopha.2020.110582_bib0095","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bbalip.2012.08.013","article-title":"Drug induced phospholipidosis: an acquired lysosomal storage disorder","volume":"1831","author":"Shayman","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2020.110582_bib0100","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.phrs.2011.03.011","article-title":"Intensity of macrolide anti-inflammatory activity in J774A.1 cells positively correlates with cellular accumulation and phospholipidosis","volume":"64","author":"Muni\u0107","year":"2011","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2020.110582_bib0105","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2217\/fvl-2018-0144","article-title":"Membrane binding proteins of coronaviruses","volume":"14","author":"J Alsaadi","year":"2019","journal-title":"Future Virol."},{"key":"10.1016\/j.biopha.2020.110582_bib0110","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/14787210.2017.1305888","article-title":"Antiviral activity of cationic amphiphilic drugs","volume":"15","author":"Salata","year":"2017","journal-title":"Expert Rev. Anti. Ther."},{"key":"10.1016\/j.biopha.2020.110582_bib0115","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijid.2020.02.018","article-title":"Discovery and development of safe-in-man broad-spectrum antiviral agents","volume":"93","author":"Andersen","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.biopha.2020.110582_bib0120","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2174\/092986708784049658","article-title":"Arbidol: a broad-spectrum antiviral compound that blocks viral fusion","volume":"15","author":"Boriskin","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.biopha.2020.110582_bib0125","first-page":"62","article-title":"Efficacy of tilorone dihydrochloride against ebola virus infection","author":"Ekins","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2020.110582_bib0130","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/minf.201200048","article-title":"Construction and consensus performance of (Q)SAR models for predicting phospholipidosis using a dataset of 743 compounds","volume":"31","author":"Orogo","year":"2012","journal-title":"Mol. Inform."},{"key":"10.1016\/j.biopha.2020.110582_bib0135","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1007\/s00204-016-1845-1","article-title":"Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man","volume":"90","author":"Dragovic","year":"2016","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.biopha.2020.110582_bib0140","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1016\/j.bmcl.2013.06.034","article-title":"Are hERG channel blockers also phospholipidosis inducers?","volume":"23","author":"Sun","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2020.110582_bib0145","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.drudis.2019.11.005","article-title":"Human ether-\u00e0-go-go-related potassium channel: exploring SAR to improve drug design","volume":"25","author":"Cavalluzzi","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2020.110582_bib0150","first-page":"20","article-title":"QSAR models for predicting five levels of cellular accumulation of lysosomotropic macrocycles","author":"Norinder","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2020.110582_bib0155","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1021\/ci400113t","article-title":"Modeling phospholipidosis induction: reliability and warnings","volume":"53","author":"Goracci","year":"2013","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.biopha.2020.110582_bib0160","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.tiv.2010.12.010","article-title":"A high content screening assay for identifying lysosomotropic compounds","volume":"25","author":"Nadanaciva","year":"2011","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.biopha.2020.110582_bib0165","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3181\/00379727-184-42462","article-title":"Structural determinants of cationic amphiphilic amines which induce clear cytoplasmic vacuoles in cultured cells","volume":"184","author":"Rorig","year":"1987","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.biopha.2020.110582_bib0170","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2020.110582_bib0175","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1021\/tx9003825","article-title":"Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds","volume":"23","author":"Hanumegowda","year":"2010","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.biopha.2020.110582_bib0180","series-title":"LiverTox Clinical and Research Information on Drug-Induced Liver Injury [Online].","author":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","year":"2012"},{"key":"10.1016\/j.biopha.2020.110582_bib0185","first-page":"25","article-title":"COVID-19, chloroquine repurposing, and cardiac safety concern: chirality might help","author":"Lentini","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2020.110582_bib0190","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fphar.2010.00137","article-title":"Stereoselective inhibition of the hERG1 potassium channel","volume":"1","author":"Grilo","year":"2010","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110582_bib0195","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.03036-14","article-title":"Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection","volume":"58","author":"Dyall","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2020.110582_bib0200","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1099\/jgv.0.001047","article-title":"Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors","volume":"99","author":"Sisk","year":"2018","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.biopha.2020.110582_bib0205","unstructured":"Medicine, N. U. S. N. L. O. ClinicalTrials.gov [Online]. Available: https:\/\/clinicaltrials.gov\/ [Accessed]."},{"key":"10.1016\/j.biopha.2020.110582_bib0210","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nchem.1961","article-title":"Imaging the intracellular distribution of tyrosine kinase inhibitors in living cells with quantitative hyperspectral stimulated Raman scattering","volume":"6","author":"Fu","year":"2014","journal-title":"Nat. Chem."},{"key":"10.1016\/j.biopha.2020.110582_bib0215","unstructured":"Fda. Fda cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems [Online]. Available: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or [Accessed]."},{"key":"10.1016\/j.biopha.2020.110582_bib0220","unstructured":"PubChem [Online]. Available: https:\/\/pubchem.ncbi.nlm.nih.gov\/ [Accessed]."},{"key":"10.1016\/j.biopha.2020.110582_bib0225","unstructured":"Administration, U. S. F. A. D. Drugs@FDA: FDA-Approved Drugs [Online] Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/ [Accessed]."},{"key":"10.1016\/j.biopha.2020.110582_bib0230","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.0954-6820.1967.tb10873.x","article-title":"Infective hepatitis and toxic jaundice in a municipal hospital during a five-year period. Incidence and prognosis","volume":"182","author":"Bjorneboe","year":"1967","journal-title":"Acta Med. Scand."},{"key":"10.1016\/j.biopha.2020.110582_bib0235","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/15563650500514558","article-title":"Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia","volume":"44","author":"Chen","year":"2006","journal-title":"Clin. Toxicol. (Phila)"},{"key":"10.1016\/j.biopha.2020.110582_bib0240","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/QAI.0b013e3181c9caac","article-title":"Pharmacokinetic\/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211)","volume":"53","author":"Crawford","year":"2010","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.biopha.2020.110582_bib0245","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00003088-199631040-00003","article-title":"Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements","volume":"31","author":"Ducharme","year":"1996","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biopha.2020.110582_bib0250","first-page":"155","article-title":"Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: a narrative review based on the study of case reports","volume":"1","author":"Hancox","year":"2013","journal-title":"Ther. Adv. Infect. Dis."},{"key":"10.1016\/j.biopha.2020.110582_bib0255","article-title":"Therapeutic areas II: cancer, Infectious diseases, inflammation & immunology and dermatology","author":"Kaneko","year":"2007","journal-title":"Comprehensiv Med. Chem. II"},{"key":"10.1016\/j.biopha.2020.110582_bib0260","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00003088-199630040-00002","article-title":"Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications","volume":"30","author":"Krishna","year":"1996","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biopha.2020.110582_bib0265","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1128\/AAC.01447-09","article-title":"Effect of vicriviroc on the QT\/corrected QT interval and central nervous system in healthy subjects","volume":"54","author":"O\u2019mara","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2020.110582_bib0270","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.yjmcc.2005.09.017","article-title":"Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel","volume":"40","author":"Ridley","year":"2006","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.biopha.2020.110582_bib0275","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/j.1552-4604.1996.tb04758.x","article-title":"The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations","volume":"36","author":"Schran","year":"1996","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110582_bib0280","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.biopha.2020.110582_bib0285","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2165\/00003088-200544090-00003","article-title":"Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial","volume":"44","author":"Shi","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biopha.2020.110582_bib0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1027309703313","article-title":"Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel","volume":"254","author":"Stanat","year":"2003","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.biopha.2020.110582_bib0295","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2125.1983.tb01501.x","article-title":"Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man","volume":"15","author":"Taylor","year":"1983","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110582_bib0300","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1517\/14740338.4.3.421","article-title":"Antimalarial drugs: QT prolongation and cardiac arrhythmias","volume":"4","author":"Traebert","year":"2005","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.biopha.2020.110582_bib0305","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0009-9236(98)90137-0","article-title":"The influence of cisapride and clarithromycin on QT intervals in healthy volunteers","volume":"64","author":"Van Haarst","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2020.110582_bib0310","doi-asserted-by":"crossref","DOI":"10.1016\/0928-0987(96)00177-7","article-title":"Pharmacokinetics of cyclizine following intravenous administration to human volunteers","author":"Walker","year":"1996","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2020.110582_bib0315","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220307757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220307757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T18:03:54Z","timestamp":1766081034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332220307757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":63,"alternative-id":["S0753332220307757"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110582","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110582","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"110582"}}